Joyce Liporace, MD
Neurology · West Chester, PANPI 1710956156
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (47.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by UCB, Inc. at 54.4% of the total. Reporting peaked in 2019 at $8,270 and has fallen 98.2% since, to $147 in 2023.
Across 29 payments — averaging $506.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$8K
- SK Life Science, Inc.$6K
- Greenwich Biosciences, Inc.$183
- Jazz Pharmaceuticals Inc.$147
- EMD Serono, Inc.$34
- Lilly USA, LLC$20
- plus $51 from 3 others
What the payments were for
- Consulting fees$5,47537%
- Speaking & faculty fees$7,00048%
- Travel & lodging$1,3159%
- Food & beverage$8956%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 11 | $7,983 |
| SK Life Science, Inc. | 9 | $6,268 |
| Greenwich Biosciences, Inc. | 2 | $183 |
| Jazz Pharmaceuticals Inc. | 1 | $147 |
| EMD Serono, Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Novartis | 1 | $16 |
| Acadia Pharmaceuticals Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,685 in reported general payments places this provider in the 80th percentile of 941 neurology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 66 | $1,555 |
| Memantine Hcl | 36 | $1,440 |
| Donepezil Hcl | 68 | $802 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 11 | $386 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 23 | $248 |
| Lamotrigine | 22 | $161 |
| Amitriptyline Hcl | 23 | $92 |
Paid to pharmacies, not to this prescriber.
Other neurology in West Chester
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Ravi DukkipatiYork$936K
- Brad KleinAbington$927K
- Stephanie Nahas-GeigerPhiladelphia$786K
- John KhouryAbington$686K
- Amit Bar-OrPhiladelphia$596K
- Behrang SaminejadAllentown$594K
- Anoopum GuptaPittsburgh$592K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.